Clinical trial · Observational
Intervention to Hepatic and Pulmonary Metastasis in Breast Cancer Patients
Intervention to Hepatic and Pulmonary Metastasis in Breast Cancer Patients: Prospective, Observational, Multi-institutional Registration Study - IMET
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The number of intervention performed for metastatic breast cancer has dramatically increased over the past 2 decades. Hepatectomy and pulmonary resection for stage IV colorectal cancer is now considered the standard of care for resectable patients with isolated hepatic and/or pulmonary disease and acceptable performance status. However, the indications for resection / intervention of breast cancer origin metastases are not as clearly defined. The aim of this study to focus on emerging data for the intervention (resection and/or radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), cyberKnife stereotactic radiosurgery) of breast cancer metastatic disease to the lung and liver, with a focus on indications for resection / intervention.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Metastasis | Breast Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| intervention | Procedure | — | UNRESOLVED |
| systemic treatment | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- lung and/or hepatic metastasis
- description
- intervention to metastasis (resection and/or radiofrequency ablation (RFA), transcatheter arterial chemoembolization (TACE), cyberKnife stereotactic radio surgery) vs no intervention (only systemic treatment)
- interventionNames
- Procedure: intervention
- Drug: systemic treatment
Primary outcomes (1)
- measure
- Overall survival (OS)
- timeFrame
- 3 years
- description
- Time interval between diagnosis and death
Secondary outcomes (2)
- measure
- Progression free survival (PFS)
- timeFrame
- 3 years
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Metastatic breast cancer (lung and/or hepatic metastasis) 18 years and older Antineoplastic treatment Exclusion Criteria: No lung and/or hepatic metastasis Below 18 years No antineoplastic treatment
References
Publications (0)
Data not yet available